Home World News PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib... World News PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 643 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and... March 7, 2023 New Class of Compounds Rewires Cancer Cells to Self-Destruct August 29, 2023 First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2... March 24, 2026 FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or... July 12, 2021 Load more HOT NEWS 37-Year-Old Mom Breaks American Marathon Record Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α Triple Therapy with Pertuzumab, Trastuzumab and Docetaxel is Feasible and Tolerable... Five Questions With…Amber.
